Conditional Survival and Time of Biochemical Recurrence of Localized Prostate Cancer in Japanese Patients Undergoing Laparoscopic Radical Prostatectomies.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 09 02 2020
accepted: 08 06 2020
pubmed: 12 7 2020
medline: 28 4 2021
entrez: 12 7 2020
Statut: ppublish

Résumé

Using conditional survival (CS) analysis, we investigated whether the duration of survival without biochemical recurrence (BCR) of prostate cancer after laparoscopic radical prostatectomies (LRP) affected the BCR rate. We also investigated the impact of well-known risk factors for BCR. Between 2002 and 2014, 627 consecutive patients underwent LRPs at our institution. Prostate-specific antigen (PSA) concentrations above 0.2  ng/mL were defined as BCR. Conditional BCR-free survival rates were determined through Kaplan-Meier analysis. Assessment of potential BCR risk factors was performed using a Cox proportional hazard analysis. The 10-year BCR-free rates after LRP increased to 82.4%, 84.5%, 86.6%, 90.1%, and 94.7% in patients surviving 1, 2, 3, 5, and 7.5 years without BCR, respectively. Multivariate analyses of age, PSA concentrations, neoadjuvant therapy, and pathological findings were performed for all patients. In all patients, positive surgical margins (PSM) and Gleason Grade Groups (GG) ≥ 4 were independent risk factors for BCR (p < 0.001, hazard ratio [HR] = 2.45; and p < 0.001, HR = 2.83, respectively,). Similarly, PSM and GG ≥ 4 were significant risk factors in patients surviving 1-5 years without BCR. No clear risk factors were observed in patients surviving > 5 years without BCR after LRPs. The BCR-free rate increased with time after LRP. It is recommended that patients with PSM, GG ≥ 4, or with both factors are strictly monitored for 5 years postoperatively. CS analysis is particularly useful for predicting the postoperative course of patients.

Identifiants

pubmed: 32651696
doi: 10.1245/s10434-020-08770-6
pii: 10.1245/s10434-020-08770-6
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1247-1253

Références

Shigeta K, Kikuchi E, Hagiwara M, et al. The conditional survival with time of intravesical recurrence of upper tract urothelial carcinoma. J Urol. 2017;198(6):1278–1285.
pubmed: 28634017
Ploussard G, de la Taille A, Moulin M, Allorys Y, Abbou C, Salomon L. Conditional disease-free survival after radical prostatectomy: recurrence risk evolution over time. Urology. 2016;94:173–179.
pubmed: 27154046
Sun M, Abdollah F, Bianchi M, et al. Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. Eur J Cancer (Oxford, England: 1990). 2012;48(10):1503–1511.
Kang M, Park JY, Jeong CW, et al. Changeable conditional survival rates and associated prognosticators in patients with metastatic renal cell carcinoma receiving first line targeted therapy. J Urol. 2018;200(5):989–995.
pubmed: 29940249
Boorjian SA, Eastham JA, Graefen M, et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol. 2012;61(4):664–675.
pubmed: 22169079
Brockman JA, Alanee S, Vickers AJ, et al. Nomogram predicting prostate cancer-specific mortality for men with biochemical recurrence after radical prostatectomy. Eur Urol. 2015;67(6):1160–1167.
pubmed: 25301759
Harshman LC, Xie W, Bjarnason GA, et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol. 2012;13(9):927–935.
Lee JW, Ali B, Yoo HM, Park CH, Song KY. Conditional survival analysis in Korean patients with gastric cancer undergoing curative gastrectomy. BMC Cancer 23 2015;15:1005.
Leitner CV, Ederer IA, de Martino M, et al. Dynamic Prognostication using conditional recurrence and progression estimates for patients with nonmuscle invasive bladder cancer. J Urol. 2016;196(1):46–51.
pubmed: 26835832
Epstein J, Egevad L, Amin M, Delahunt B, Srigley J, Humphrey P. The 2014 international society of urological pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–252.
Henson DE, Ries LA. On the estimation of survival. Semin Surg Oncol. 1994;10(1):2–6.
Kim W, Lee HY, Jung SH, et al. Dynamic prognostication using conditional survival analysis for patients with operable lung adenocarcinoma. Oncotarget. 9 2017;8(19):32201–32211.
pubmed: 27793026
Kim Y, Ejaz A, Spolverato G, et al. Conditional survival after surgical resection of gastric cancer: a multi-institutional analysis of the us gastric cancer collaborative. Ann Surg Oncol. 2015;22(2):557–564.
pubmed: 25287440
Wancata LM, Banerjee M, Muenz DG, Haymart MR, Wong SL. Conditional survival in advanced colorectal cancer and surgery. J Surg Res. 2016;201(1):196–201.
pubmed: 26850202
Llukani E, Lepor H. Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy. BJU Int.. 2017;120(4):505–510.
pubmed: 28220652
Murray NP. Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management. Biol Res. 4 2018;51(1):32.
Liesenfeld L, Kron M, Gschwend JE, Herkommer K. Prognostic factors for biochemical recurrence more than 10 years after radical prostatectomy. J Urol. 2017;197(1):143–148.
pubmed: 27418452

Auteurs

Masayoshi Kawakami (M)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Masanori Hasegawa (M)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. hasemsky@gmail.com.

Koichiro Yamada (K)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Keisuke Shigeta (K)

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Izumi Hanada (I)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Tatsuya Otaki (T)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Kentaro Nagao (K)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Tatsuya Umemoto (T)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Yuuki Shimizu (Y)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Hakushi Kim (H)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Nobuyuki Nakajima (N)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Masahiro Nitta (M)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Kazuya Hanai (K)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Yoshiaki Kawamura (Y)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Sunao Shoji (S)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Akira Miyajima (A)

Department of Urology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH